Skip to main content
. Author manuscript; available in PMC: 2010 Apr 1.
Published in final edited form as: Clin Pharmacol Ther. 2007 Jul 4;83(2):300–306. doi: 10.1038/sj.clpt.6100282

Table 2.

Week-2 and -56 pharmacokinetic characteristics of nelfinavir

Dose CL/F
AUC8 Cmin Cmax
Statistic (mg) (mg/kg) (mg/m2) (mg h/l) (mg/l) (mg/l) (l/h/kg) (l/h/m2)
Nelfinvair, n=50
    Mean 606 24 637 22 1.44 4.15 2.32 61.8
    Median 500 24 636 20 1.07 3.90 1.11 30.8
    SD 147 5 102 13 1.39 2.15 4.49 110.4
    %CV 24.3 21.1 16.0 59.5 96.4 51.7 193.8 178.8
    Minimum 250 8 274 1 BLQ 0.28 0.36 13.6
    Maximum 750 30 786 50 6.12 8.85 29.16 705.8
Efavirenz, n=33a
    Mean 648 24 656 16 0.87 3.05 2.07 55.0
    Median 750 24 652 15 0.35 2.80 1.64 45.6
    SD 128 6 120 8 0.95 1.20 1.38 33.9
    %CV 19.7 24.4 18.4 50.3 108.7 39.3 66.8 61.6
    Minimum 400 8 368 4 BLQ 1.2 0.32 14.6
    Maximum 750 41 987 34 3.70 6.00 5.64 143.8

AUC, area under the plasma concentration–time curve from time 0 to 8 h post-dose; BLQ, below the limit of quantitation; Cmin, minimum measured concentration; CL/F, apparent oral clearance; Cmax, observed maximum concentration; %CV, % coefficient of variation.

a

One AUC was not evaluable.